Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose-escalation, Dose-expansion, Phase 1 Study to Evaluate the Tolerability, Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Effect of ASCA101 in Patients With Advanced Solid Tumors

NCT05547906 is registered in ClinicalTrials.gov with MetaFines as lead sponsor.

NCT NCT05547906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05547906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose-escalation, Dose-expansion, Phase 1 Study to Evaluate the Tolerability, Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Effect of ASCA101 in Patients With Advanced Solid Tumors
Lead sponsor
MetaFines
Phase
Phase 1
Overall status
Completed
Start date
November 8, 2021
Completion date
February 29, 2024
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor